SCHEMBL22553652

SCHEMBL22553652

CSc1ncc2c(C)cc(=O)n([C@@H]3CCC[C@]3(C)F)c2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCND1 P24385 20/20 0.40
CDK4 P11802 18/20 0.40
CCND3 P30281 17/20 0.40
CDK6 Q00534 4/20 0.40
CCND2 P30279 16/20 0.37
NUAK1 O60285 2/20 0.36
MARK3 P27448 1/20 0.36
MARK2 Q7KZI7 1/20 0.36
MARK4 Q96L34 1/20 0.36
NUAK2 Q9H093 1/20 0.36
MARK1 Q9P0L2 1/20 0.36
CCNB2 O95067 1/20 0.36
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
CCNB3 Q8WWL7 1/20 0.36
FGFR1 P11362 1/20 0.35
FGFR2 P21802 1/20 0.35
FGFR4 P22455 1/20 0.35
FGFR3 P22607 1/20 0.35
CCNE1 P24864 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22553453 1.00 CCND1 (0.40) CCND1CDK4CCND3CDK6CCND2
SCHEMBL30839147 0.88 CCNE1 (0.41) CCND1CDK4CCND3CDK6CCNE1
SCHEMBL22553527 0.88 CCNE1 (0.41) CCND1CDK4CCND3CDK6CCNE1
SCHEMBL22553576 0.82 CCND1 (0.37) CCND1CDK4CCND3CDK6CCND2
SCHEMBL22553575 0.82 CCND1 (0.37) CCND1CDK4CCND3CDK6CCND2
SCHEMBL22553458 0.82 CCND1 (0.46) CCND1CDK4CCND3CDK6CCND2
SCHEMBL22553604 0.82 CCND1 (0.46) CCND1CDK4CCND3CDK6CCND2
SCHEMBL2622290 0.80 CDK4 (0.53) CCND1CDK4CCND3CCND2NUAK1
SCHEMBL29507738 0.80 CDK4 (0.53) CCND1CDK4CCND3CCND2NUAK1
SCHEMBL22553521 0.79 CCND1 (0.62) CCND1CDK4CCND3CDK6CCND2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3956031-A1 ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH Pfizer Inc. (US) 2022-02-23 EP disclosed
US-11203594-B2 Anti-proliferative agents for treating PAH PFIZER INC. (US) 2021-12-21 US disclosed
US-11203594-B2 Anti-proliferative agents for treating PAH PFIZER INC. (US) 2021-12-21 US disclosed
US-20200331909-A1 ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH PFIZER INC. (US) 2020-10-22 US disclosed
US-20200331909-A1 ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH PFIZER INC. (US) 2020-10-22 US disclosed
WO-2020212865-A1 ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH PFIZER INC. (US) 2020-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11203594-B2 Anti-proliferative agents for treating PAH EDNRB, EDNRA, PAH CCND1 108/4885CDK4 219/4885CCND3 143/4885
US-20200331909-A1 ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH EDNRB, EDNRA, PAH CCND1 108/4885CDK4 219/4885CCND3 143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.